Related by context. All words. (Click for frequent words.) 84 Phase 1b 81 Phase 1b clinical 81 Phase Ib clinical 81 phase IIb 80 Phase IIa 80 Phase 2a 80 Phase 2b trial 79 Phase 2b study 79 Phase IIb 79 Phase III clinical 79 phase IIa 79 Phase 2a trial 78 phase IIa clinical 78 phase IIb clinical 78 Phase IIb trial 78 Phase 2b clinical 78 Phase IIa trial 78 Phase 1a 78 Phase III 78 Phase 2a clinical 78 Phase Ib II 78 Phase 1b trial 77 Phase Ib study 77 Phase Ia 77 Phase IIa clinical 77 phase Ib 77 Phase IIb clinical 76 dose escalation trial 75 pivotal Phase III 75 Phase IIIb clinical 75 phase 2a 75 dose escalation study 75 Phase 2b 75 confirmatory Phase III 74 Phase #b/#a 74 Phase II 74 Phase IIb trials 74 dose escalation Phase 74 Phase IIa trials 73 INCB# [001] 73 placebo controlled Phase 73 dose escalation 72 registrational 72 multiple ascending dose 72 Phase III clinical trials 72 Phase III pivotal 72 Phase Ib clinical trials 72 PXD# 72 multicenter Phase 71 ganetespib 71 alvespimycin 71 phase Ib clinical 71 Phase III trials 71 IIa trial 71 randomized Phase 71 Phase IIIb 71 pivotal Phase 71 Phase 1a clinical 70 multicenter Phase II 70 phase IIb study 70 phase IIb trial 70 CR# vcMMAE 70 Phase #/#a 70 dirucotide 70 confirmatory Phase 3 70 randomized Phase III 70 GALNS 70 Phase 2b clinical trials 69 Cloretazine ® 69 HGS ETR1 69 deforolimus 69 Phase IIb clinical trials 69 elotuzumab 69 clinical trial 69 Phase #b/#a clinical 69 HGS# 69 tanespimycin 69 JAK inhibitor 69 placebo controlled Phase III 69 axitinib 69 Cloretazine R VNP#M 69 registrational trial 69 lintuzumab 69 dose escalation clinical 69 AP# [003] 69 IMGN# 69 APEX PD 69 pharmacokinetic PK 69 dose cohorts 69 placebo controlled clinical 69 ongoing Phase 1b 69 enzastaurin 68 blinded randomized placebo controlled 68 Dacogen injection 68 randomized controlled Phase 68 GLP toxicology studies 68 oral ridaforolimus 68 Alocrest 68 tolerability 68 single ascending dose 68 Phase III randomized controlled 68 Phase IIB 68 Phase IIa clinical trials 68 AEG# 68 placebo controlled 68 MEND CABG 68 FOLOTYN ® 68 glufosfamide 68 perifosine 68 relapsed refractory multiple myeloma 68 randomized Phase 2b 68 IND enabling 68 huC# DM4 68 VEGF Trap 68 double blinded placebo 68 Phase III confirmatory 68 viral kinetic 68 PRX # 67 SUCCEED trial 67 Phase 1b clinical trials 67 obatoclax 67 randomized Phase IIb 67 ATL# [001] 67 Phase Ib IIa 67 SCH # 67 forodesine 67 BRIM2 67 pivotal bioequivalence 67 TACI Ig 67 Phenoptin 67 pertuzumab 67 pharmacokinetic PK study 67 ascending dose 67 Marqibo 67 dose dose escalation 67 Archexin 67 pharmacokinetics PK 67 multicenter randomized placebo controlled 67 preclinical 67 NGX# 67 R#/MEM # 67 Sym# 67 IMC A# 67 RDEA# 67 Phase 2a clinical trials 67 PSN# [002] 67 preclinical studies 67 ELACYT 66 MGCD# [001] 66 OncoVEX GM CSF 66 RSD# oral 66 PEG PAL 66 Amrubicin 66 IMA# 66 PEG Interferon lambda 66 aflibercept 66 CEQ# 66 ADVANCE PD 66 LibiGel Phase III 66 BRIM3 66 EndoTAG TM -1 66 Urocidin 66 Phase 2b randomized 66 Phase 66 AQ4N 66 carfilzomib 66 rNAPc2 66 ARRY 66 BCX# 66 NP2 Enkephalin 66 label dose escalation 66 OvaRex ® MAb 66 cannabinor 66 initiate Phase IIb 66 clinical pharmacology studies 66 relapsed multiple myeloma 66 KRN# 66 ofatumumab 66 TMC# C# 66 mipomersen 66 belinostat 66 Phase #b/#a trial 66 elacytarabine 66 IIa clinical 66 Phase IIb Clinical Trial 66 XL# [003] 66 PF # [001] 66 safety tolerability 66 initiate Phase 66 NVA# 66 Plicera 66 Annamycin 66 daclizumab 66 masked placebo controlled 66 CA4P 66 phase IIb III 66 sunitinib malate 66 MBP# [001] 66 RG# [001] 66 multicenter Phase III 66 lorvotuzumab mertansine 66 MEK inhibitor 66 multicenter phase 66 Alzhemed TM 66 AEGR 66 Allovectin 7 R 65 dosing cohort 65 DermaVir Patch 65 Cloretazine 65 CoFactor 65 BAY #-# 65 HCV SPRINT 65 Initiate Phase 65 BLA submission 65 pharmacokinetic 65 sapacitabine 65 otelixizumab 65 clinical trials 65 celgosivir 65 rALLy clinical trial 65 TG# [001] 65 PDX pralatrexate 65 pharmacodynamic PD 65 tesmilifene 65 Amigal 65 EOquin 65 oral prodrug 65 multicentre randomized 65 HuMax CD4 65 Fx #A 65 ENDEAVOR IV 65 docetaxel Taxotere R 65 Phase III randomized 65 ocrelizumab 65 TG MV 65 ISIS # 65 CRLX# 65 Omacetaxine 65 ALN TTR# 65 huN# DM1 65 REOLYSIN ® 65 oral deforolimus 65 PRT# 65 SAR# [004] 65 Phase III psoriasis 65 tolerated dose MTD 65 ProLindac 65 GRN#L 65 Zenvia ™ 65 Phase III Pivotal 65 LUX Lung 65 HuMax EGFr 65 multicenter randomized Phase 65 blind randomized placebo 65 initiate Phase 1b 65 OXi# 65 nab paclitaxel 65 Perifosine 65 dose cohort 65 IND submission 65 PRTX 65 initiate Phase Ib 65 tezampanel NGX# 65 PLK1 SNALP 65 randomized multicenter 65 IDX# 65 initiate Phase 2b 65 ascending doses 65 PEG SN# 65 pharmacokinetic studies 65 PSMA ADC 65 TASKi2 65 European Sepsis Trial 64 tremelimumab 64 Ozarelix 64 Pivotal Trial 64 vidofludimus 64 Bicifadine 64 investigational compound 64 HspE7 64 multicenter clinical 64 DASISION 64 lomitapide 64 evaluating tivozanib 64 MDV# 64 neratinib 64 Phase #/#a trial 64 hypoxia activated prodrug 64 Phase IIb III 64 velafermin 64 EOquin TM 64 NOX E# 64 Pivotal Phase III 64 YONDELIS 64 Azedra 64 AeroLEF TM 64 Phase III Clinical Trial 64 VNP#M 64 voreloxin 64 OvaRex R 64 dacetuzumab 64 MEK inhibitor RDEA# 64 Traficet EN 64 COU AA 64 bicifadine 64 torezolid phosphate 64 palifosfamide 64 entinostat 64 HDAC Inhibitor 64 MEND CABG II 64 Phase 2b Clinical Trial 64 IIb clinical trial 64 MLN# 64 metastatic hormone refractory 64 riociguat 64 blinded placebo controlled 64 INCB# [002] 64 BLA filing 64 virus HCV protease inhibitor 64 ILLUMINATE 64 multicenter randomized double 64 HER2 positive metastatic breast 64 Ostarine 64 pharmacodynamics 64 Daclizumab 64 NO# [002] 64 L BLP# 64 QLT# 64 blinatumomab 64 II Clinical Trial 64 mapatumumab 64 ASA# 64 adecatumumab 64 SNT MC# 64 vosaroxin 64 XmAb# 64 Fibrillex TM 64 MGCD# [002] 64 XL# XL# XL# 64 TMC# [002] 64 Initiated Phase 64 Phase 1b dose escalation 64 CYT# 64 IL# PE#QQR 64 Aplidin 64 PD LID 64 Triolex 64 Exherin TM 64 pomalidomide 64 Phase III placebo controlled 64 dosing cohorts 64 selective androgen receptor modulator 64 alvimopan 64 MOZOBIL 64 double blind placebo 64 Allovectin 7 64 prospective randomized placebo 64 dirucotide MBP# 64 ruxolitinib 64 placebo controlled randomized 64 confirmatory clinical 64 Phase IIb Trial 63 Carfilzomib 63 budesonide foam 63 mertansine 63 Tyrima 63 dyskinesia PD LID 63 Maximum Tolerated Dose 63 ELND# 63 seliciclib CYC# 63 randomized placebo controlled 63 pharmacokinetics 63 PDE4 inhibitor 63 severe hypercholesterolemia 63 velafermin belinostat 63 Phase III Trial 63 ixabepilone 63 CRx 63 trastuzumab DM1 T DM1 63 MAA submission 63 Randomized Phase 63 Corlux 63 PS# [001] 63 EFAPROXYN 63 IIa clinical trial 63 Ceflatonin 63 GetGoal Phase III 63 valopicitabine 63 Azixa 63 CBLC# 63 Zenvia Phase III 63 CHAMPION PCI 63 Aflibercept 63 clofarabine 63 sorafenib Nexavar ® 63 Androxal TM 63 teduglutide 63 TELINTRA 63 AZILECT R 63 receptor tyrosine kinase inhibitor 63 GAMMAGARD 63 TELCYTA 63 preclinical efficacy 63 ataluren 63 Bezielle 63 CB2 selective receptor agonist 63 HCD# [002] 63 Panzem R NCD 63 Troxatyl 63 brivaracetam 63 Golimumab 63 prospective multicenter 63 optimal dosing regimen 63 ZYBRESTAT 63 Asentar 63 histone deacetylase HDAC inhibitor 63 BIBW 63 safety tolerability pharmacokinetics 63 subcutaneous formulation 63 Pivotal Phase 63 PANVAC VF 63 eniluracil 63 Virulizin R 63 ONCONASE 63 Allovectin 7 ® 63 ILUVIEN ® 63 ANCHOR trial 63 imetelstat 63 EchoCRT 63 romidepsin 63 Reolysin 63 Xanafide 63 CCX# 63 blinded randomized 63 NDA submission 63 multicenter placebo controlled 63 T DM1 63 Blinatumomab 63 octreotide implant 63 RhuDex ® 63 cell lymphoma CTCL 63 ThermoDox R 63 Phase 2b kidney transplant 63 Pimavanserin 63 treatment naive genotype 63 ALN RSV# 63 HGS ETR2 63 Laquinimod 63 AIR CF1 63 HCV protease inhibitor 63 OPT CHF 63 Tarvacin TM 63 fosbretabulin 63 APTIVUS 63 double blinded randomized 63 randomized clinical 63 MAP# 63 bavituximab 63 TOCOSOL Paclitaxel 63 HuMax CD# 63 unblinded 63 pegloticase 63 Diamyd ® 63 Aurora kinase inhibitor 63 TKB# 63 BLOOM DM 63 afatinib 63 GLPG# 63 fostamatinib 63 Mipomersen 63 trastuzumab emtansine T DM1 63 Restanza 63 Ophena TM 63 TBC# 63 APPRAISE 63 PA# [002] 63 MAGE A3 ASCI 63 midstage trials 62 Cloretazine R 62 COMFORT II 62 Locteron 62 Microplasmin 62 IMC #B 62 XL# XL# XL# XL# 62 CCX# B 62 bardoxolone 62 Phase 2b monotherapy 62 TRO# 62 Chemophase 62 refractory CLL 62 multicenter randomized controlled 62 Altastaph 62 bosutinib 62 dexpramipexole 62 oral methylnaltrexone 62 bendamustine 62 Elagolix 62 albinterferon alfa 2b 62 Virulizin ® 62 Phase III TRIST 62 NXL# 62 AEZS 62 Shigamabs ® 62 LCP AtorFen 62 Quinamed 62 tezampanel 62 tolevamer 62 multicenter 62 heavily pretreated 62 Vicriviroc 62 registrational studies 62 OMP #M# 62 Panzem R 62 MERLIN TIMI 62 galiximab 62 dimebon 62 Zerenex 62 Icatibant 62 ozarelix 62 controlled multicenter 62 ONCONASE R 62 AVADO 62 Fodosine 62 opioid induced bowel dysfunction 62 diabetic neuropathic pain 62 vascular disrupting agent 62 SYMMETRY trial 62 methylnaltrexone 62 compound INCB# 62 denufosol 62 lintuzumab SGN 62 Hyphanox 62 PREOS R 62 elagolix 62 Aurexis 62 investigational humanized monoclonal antibody 62 ZYBRESTAT fosbretabulin 62 eltrombopag 62 assessing T DM1 62 LEP ETU 62 CCR5 antagonist 62 reslizumab 62 Factor VIIa 62 FOLOTYN 62 Synavive 62 FavId 62 initiated Phase Ib 62 laquinimod 62 antibody MAb 62 FOLFOX6 chemotherapy regimen 62 phase III ACCLAIM 62 pradefovir 62 ToGA 62 rALLy trial 62 nonclinical studies 62 ISTODAX 62 HCV RESPOND 2 62 oral formulation 62 RGB # 62 Tesetaxel 62 Sapacitabine 62 LibiGel ® 62 PFO migraine 62 AKT inhibitor 62 sorafenib Nexavar 62 KNS # 62 Cethromycin 62 COSIRA trial 62 OncoVEX 62 ocular formulation 62 LUMINATE 62 dose escalation phase 62 AIR CF2 62 rindopepimut 62 label multicenter 62 refractory metastatic colorectal cancer 62 gemcitabine Gemzar ® 62 Glufosfamide 62 CIMZIA TM 62 miconazole Lauriad ® 62 dextromethorphan quinidine 62 pharmacodynamic effects 62 custirsen 62 AZD# 62 StemEx 62 GW# [003] 62 trodusquemine 62 PHX# 62 pharmacodynamic 62 Prostate AdenoCarcinoma Treatment 62 HuLuc# 62 unblinding 62 PREOS 62 generation purine nucleoside 62 picoplatin 62 APEX AMI trial 62 isavuconazole 62 CRMD# 62 metaglidasen 62 LE SN# 62 IMPACT IMmunotherapy 62 temsirolimus 62 ALN TTR 62 acyclovir Lauriad R 62 pralatrexate 62 Aryplase 62 cathepsin K inhibitor 62 randomized double 62 eprotirome 61 monotherapy 61 investigational monoclonal antibody 61 Spiegelmer ® 61 ularitide 61 vicriviroc 61 RE LY ® 61 NABTT 61 baminercept 61 ridaforolimus 61 lumiliximab 61 peginesatide 61 Enzastaurin 61 LEUKINE 61 NCCTG 61 paclitaxel poliglumex 61 PROSTVAC TM 61 orally bioavailable 61 ROCKET AF 61 resminostat 61 Proxinium TM 61 Medidur TM FA 61 MT#/MEDI-# 61 ALN PCS 61 GATTEX TM 61 Nanobody 61 Velcade bortezomib 61 sNDA submission 61 Phase IIIb study 61 TOLAMBA 61 Pivotal Study 61 tramiprosate Alzhemed TM 61 Oglemilast 61 Neuradiab 61 Phase 2b Trial 61 Phase III Clinical Trials 61 RE SURGE 61 PNP inhibitor 61 farletuzumab 61 investigational drug 61 talactoferrin 61 relapsed MM 61 Ocrelizumab 61 Phase III HEAT 61 multicenter randomized 61 tivozanib 61 CAMMS# 61 Zenvia TM 61 zanolimumab 61 Voreloxin 61 GSK# [001] 61 Alpharadin 61 active comparator 61 olaparib 61 randomized controlled multicenter 61 Luveniq 61 Clavis Pharma 61 IIa trials 61 REVIVE Diabetes 61 ceftaroline 61 Multiple Ascending Dose 61 Tezampanel 61 Onrigin 61 dose limiting toxicities 61 refractory chronic lymphocytic 61 RH1 61 Romidepsin 61 randomized blinded 61 lesinurad 61 oritavancin 61 davunetide intranasal AL 61 prospective multicenter randomized 61 ulimorelin 61 teriflunomide 61 Phase 2a Clinical Trial 61 CLARITY study 61 treatment naïve genotype 61 IRX 2 61 phase IIIb 61 inhibitor RG# 61 alemtuzumab Campath 61 Tarceva TM 61 LE DT 61 BCIRG 61 Genasense ® 61 multicentre 61 TLK# 61 ASONEP 61 XL# SAR# 61 Stedivaze 61 Hedgehog Pathway Inhibitor 61 PCK# 61 DSMB 61 satraplatin Phase 61 DR Cysteamine 61 candidate AQ4N 61 orally administered inhibitor 61 abiraterone acetate 61 metastatic castration resistant 61 dosing regimens 61 CD# CEA 61 RSD# 61 safety tolerability pharmacokinetic 61 atacicept 61 nitazoxanide 61 ThermoDox ® 61 tesetaxel 61 PRECISE trial 61 JAK2 inhibitor 61 RAV# 61 cetrorelix 61 Diabetic Macular Edema DME 61 ALN VSP 61 CUDC 61 ALTU 61 Personalized Immunotherapy 61 Ceflatonin R 61 Combination REOLYSIN R 61 Imprime PGG 61 Zybrestat 61 Exelixis XL# 61 eosinophilic asthma 61 PRE SURGE 61 IAP inhibitors 61 ORMD 61 mRCC 61 Tanespimycin 61 CLORETAZINE TM VNP#M 61 RhuDex 61 Clolar ® 61 PEP# [003] 61 CTCE 61 arzoxifene 61 atrasentan 61 visilizumab 61 omacetaxine mepesuccinate 61 Tamibarotene 61 Pralatrexate 61 AVN# [001] 61 APTIVUS r 61 BrachySil TM 61 Triapine 61 trial evaluating PRX# 61 tolerability pharmacokinetics 61 Telatinib 61 randomized multicentre 61 initiate Phase IIa 61 humanized anti 61 Actilon 61 ponatinib 61 unique alkylating agent 61 NSABP 61 cutaneous T cell 61 Safinamide 61 ADAGIO study 61 randomized multicenter Phase III 61 mCRC 61 tgAAC# 61 StemEx R 61 midstage clinical 61 Atiprimod 61 ADX# 61 GV# [001] 61 Bortezomib 61 incyclinide 61 Lovaxin C 61 Phase IIb kidney transplant 60 preclinically 60 PrevOnco 60 LEVADEX 60 PRECISE Trial 60 metastatic renal cell carcinoma 60 depsipeptide 60 regorafenib 60 generation PNP inhibitor 60 Ridaforolimus 60 OncoGel 60 Dyloject TM 60 cilengitide 60 prospective randomized multicenter 60 BR.# 60 microplasmin 60 ZACTIMA 60 rALLy 60 LymphoStat B TM 60 ICA # 60 Serdaxin ® 60 Board DSMB 60 perifosine KRX 60 randomized controlled 60 fidaxomicin Phase 3 60 immunogenicity 60 BNC# 60 cardio renal 60 Atu# 60 eculizumab 60 anticancer compound 60 randomized discontinuation trial 60 Phase III ALLEGRO 60 EGS# 60 Pharmacokinetics PK 60 Omnitarg 60 Locteron ® 60 glucokinase activator 60 PrevOnco ™ 60 polymerase inhibitor 60 dacetuzumab SGN 60 bortezomib Velcade 60 ABSORB trial 60 oral rivaroxaban 60 vernakalant oral 60 mGluR5 negative 60 tolerability profile 60 BEMA TM Fentanyl 60 SUTENT 60 Augment Injectable 60 BrachySil 60 Denufosol 60 PROSTVAC ® 60 ITAX 60 nalbuphine ER 60 Bronchitol 60 GAP #B# 60 GSK# [002] 60 FAME Study 60 Phase III Trials 60 seliciclib 60 investigational compounds 60 sunitinib 60 interferon gamma 1b 60 null responder HCV 60 PROPEL trial 60 Debio 60 cystinosis patients 60 Proellex TM 60 Vitaxin 60 crofelemer 60 BRAF inhibitor 60 docetaxel chemotherapy 60 SPIRIT FIRST 60 Phase IIa proof 60 ISTODAX ® 60 GRN# 60 LymphoStat B 60 AzaSite Plus 60 liposomal formulation 60 immunotherapeutic agent 60 leading oral taxane 60 Vilazodone 60 XL# anticancer compounds 60 LCP Tacro 60 MORAb 60 carboplatin paclitaxel 60 pafuramidine 60 Dose escalation 60 amrubicin 60 Parkinson disease levodopa induced 60 CALGB 60 TPI ASM8 60 danoprevir 60 Alfimeprase 60 SinuNase TM 60 Cannabinor 60 evaluating satraplatin 60 PROMACTA 60 subcutaneously administered 60 AVE# 60 Diabetic Macular Edema 60 EVEREST II 60 orally administered 60 Phase lll 60 ganaxolone 60 investigational pan BCR 60 adecatumumab MT# 60 oral picoplatin 60 APD# 60 Onconase 60 Relovair 60 Myocet 60 secondary efficacy endpoints 60 metastatic castrate resistant 60 Dalbavancin 60 OHR/AVR# 60 Veronate 60 ANTEGREN 60 Aplidin R 60 Maximum Tolerated Dose MTD 60 placebo controlled clinical trials 60 telaprevir VX 60 TYKERB 60 Nexavar sorafenib 60 Symadex 60 Taxotere ® 60 castrate resistant prostate cancer 60 Hsp# Inhibitor 60 thymalfasin 60 advanced carcinoid 60 refractory multiple myeloma 60 CYT# potent vascular disrupting 60 ofatumumab HuMax CD# 60 ThGRF 60 PEGPH# 60 Dapagliflozin 60 generation proteasome inhibitor 60 MyVax R 60 HQK 60 Cotara 60 Ixempra 60 MGd 60 Vicinium TM 60 Kahalalide F 60 Hepatocellular Carcinoma HCC 60 dependent kinase inhibitor 60 Randomized Phase II 60 non nucleoside inhibitor 60 Lu AA# 60 ALKS 60 LAF# 60 volociximab 60 Phase III VISTA 60 aclidinium 60 DU #b 60 brentuximab vedotin 60 Meets Primary Endpoint 60 neurogenic orthostatic hypotension 60 JZP 60 EVIZON 60 Darusentan 60 melphalan prednisone 60 GRNVAC1 60 CCR5 mAb 60 RELOVAIR ™ 60 crizotinib PF # 60 6R BH4 60 PRECiSE 60 trastuzumab DM1 60 Azedra TM 60 recurrent malignant glioma 60 UPLYSO 60 Initiates Phase II 60 RG# ITMN 60 triphendiol 60 tiapamil 60 XL# XL# 60 Investigational Device Exemption IDE 60 metastatic renal cell 60 ALN VSP Phase 60 elesclomol 60 varespladib 60 maribavir 60 mixed dyslipidemia 60 PI3K/Akt pathway inhibitor 60 metastatic HRPC 60 IPL# 60 Phase III registrational 60 CLL8 60 label multicenter Phase 60 Nuvion 60 INCB# [003] 60 AZX# 60 novel VDA molecule 60 T Pred 60 BiTE antibody 60 relapsed refractory 60 DB# [003] 60 Pharmacokinetic PK 60 urocortin 2 60 IMPACT DCM 60 Onalta ™ 60 RE LY 60 administered subcutaneously 60 JAK1 60 tecarfarin 60 AZILECT ® 60 Viramidine 60 Solazed 60 preclinical toxicology 60 Opexa 60 standard chemotherapy regimen 60 albiglutide 60 Cintredekin Besudotox 60 Antiviral Activity 60 GSK # 60 LymphoStat B belimumab 60 novel histone deacetylase 60 Pazopanib 60 Entereg R 60 maximally tolerated dose 60 TKM ApoB 60 Phase III multicenter 60 DDP#